Dieter Henrik Heiland1,2, Gerrit Haaker3,4, Ralf Watzlawick3,4, Daniel Delev3,4, Waseem Masalha3,4, Pamela Franco3,4, Marcia Machein3,4, Ori Staszewski5,4, Oliver Oelhke6,4, Nils Henrik Nicolay6,4, Oliver Schnell3,4. 1. Department of Neurosurgery, Medical Center, University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany. dieter.henrik.heiland@uniklinik-freiburg.de. 2. Faculty of Medicine, University of Freiburg, Freiburg, Germany. dieter.henrik.heiland@uniklinik-freiburg.de. 3. Department of Neurosurgery, Medical Center, University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany. 4. Faculty of Medicine, University of Freiburg, Freiburg, Germany. 5. Institute of Neuropathology, Medical Center, University of Freiburg, Freiburg, Germany. 6. Radiation Clinic, Medical Center, University of Freiburg, Freiburg, Germany.
Abstract
INTRODUCTION: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with peak incidence in patients older than 65 years. These patients are mostly underrepresented in clinical trials and often undertreated due to concomitant diseases. Recently, different therapeutic approaches for elderly patients with GBM were discussed. To date, there is no defined standard treatment. The aim of the present study is to evaluate the functional and oncological outcome in surgical treatment of elderly patients. MATERIALS AND METHODS: A total of 342 elderly patients aged ≥ 65 years were retrospectively analyzed in our neurosurgical center. Surgical therapy, adjuvant treatment, overall survival (OS) and functional outcome using Karnofsky performance scale (KPS) and Neurological assessment of neuro-oncology-score were analyzed. RESULTS: The median age at GBM diagnosis was 73.4 (IQR 9.28) years. Median overall survival was 7.5 (CI 95% 6.0-9.1) months and median preoperative or postoperative KPS was 80 (IQR 20). Surgical resection was performed in 216 (63.2%) patients, in 125 patients (36.5%) patients a stereotactic biopsy was performed. The median OS was significantly higher in patients with gross total resection (GTR) compared to partial resection and biopsy (10.8 months; CI 95% 9.5-12.3). Patients with combined radio- and chemo-therapy (RCT) showed significant longer OS, particularly MGMT-negative GBM. Higher preoperative KPS was found to be associated with improved overall survival. CONCLUSION: GTR and adjuvant combined RCT provides benefits for overall survival in elderly patients. Therapy decision should be made in regard to preoperative functional status instead of biological age.
INTRODUCTION:Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with peak incidence in patients older than 65 years. These patients are mostly underrepresented in clinical trials and often undertreated due to concomitant diseases. Recently, different therapeutic approaches for elderly patients with GBM were discussed. To date, there is no defined standard treatment. The aim of the present study is to evaluate the functional and oncological outcome in surgical treatment of elderly patients. MATERIALS AND METHODS: A total of 342 elderly patients aged ≥ 65 years were retrospectively analyzed in our neurosurgical center. Surgical therapy, adjuvant treatment, overall survival (OS) and functional outcome using Karnofsky performance scale (KPS) and Neurological assessment of neuro-oncology-score were analyzed. RESULTS: The median age at GBM diagnosis was 73.4 (IQR 9.28) years. Median overall survival was 7.5 (CI 95% 6.0-9.1) months and median preoperative or postoperative KPS was 80 (IQR 20). Surgical resection was performed in 216 (63.2%) patients, in 125 patients (36.5%) patients a stereotactic biopsy was performed. The median OS was significantly higher in patients with gross total resection (GTR) compared to partial resection and biopsy (10.8 months; CI 95% 9.5-12.3). Patients with combined radio- and chemo-therapy (RCT) showed significant longer OS, particularly MGMT-negative GBM. Higher preoperative KPS was found to be associated with improved overall survival. CONCLUSION: GTR and adjuvant combined RCT provides benefits for overall survival in elderly patients. Therapy decision should be made in regard to preoperative functional status instead of biological age.
Authors: Kaisorn L Chaichana; Khan K Chaichana; Alessandro Olivi; Jon D Weingart; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2010-10-01 Impact factor: 5.115
Authors: Georgia Harris; Dasantha Jayamanne; Helen Wheeler; Cecelia Gzell; Marina Kastelan; Geoff Schembri; David Brazier; Raymond Cook; Jonathan Parkinson; Mustafa Khasraw; Sandra Louw; Michael Back Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-21 Impact factor: 7.038
Authors: D S Tsang; L Khan; J R Perry; H Soliman; A Sahgal; J L Keith; T G Mainprize; S Das; L Zhang; M N Tsao Journal: Clin Oncol (R Coll Radiol) Date: 2014-12-27 Impact factor: 4.126
Authors: Ranjith Babu; Jordan M Komisarow; Vijay J Agarwal; Shervin Rahimpour; Akshita Iyer; Dylan Britt; Isaac O Karikari; Peter M Grossi; Steven Thomas; Allan H Friedman; Cory Adamson Journal: J Neurosurg Date: 2015-10-09 Impact factor: 5.115
Authors: Shota Tanaka; Fredric B Meyer; Jan C Buckner; Joon H Uhm; Elizabeth S Yan; Ian F Parney Journal: J Neurosurg Date: 2012-11-23 Impact factor: 5.115
Authors: Jacob S Young; Steven J Chmura; Derek A Wainwright; Bakhtiar Yamini; Katherine B Peters; Rimas V Lukas Journal: J Neurol Sci Date: 2017-08-01 Impact factor: 3.181
Authors: Michael Youssef; Ethan B Ludmir; Jacob J Mandel; Akash J Patel; Ali Jalali; Jeffrey Treiber; Jimin Wu; Mary Frances McAleer; John F de Groot Journal: J Neurooncol Date: 2019-10-23 Impact factor: 4.130
Authors: Mateo Tomas Fariña Nuñez; Pamela Franco; Debora Cipriani; Nicolas Neidert; Simon P Behringer; Irina Mader; Daniel Delev; Christian Fung; Jürgen Beck; Roman Sankowski; Nils Henrik Nicolay; Dieter Henrik Heiland; Oliver Schnell Journal: J Neurooncol Date: 2020-01-13 Impact factor: 4.130
Authors: Brandon A Sherrod; Nicholas T Gamboa; Christopher Wilkerson; Herschel Wilde; Mohammed A Azab; Michael Karsy; Randy L Jensen; Sarah T Menacho Journal: J Neurooncol Date: 2019-05-04 Impact factor: 4.130
Authors: Aisling M Glynn; Guhan Rangaswamy; Julianne O'Shea; Mary Dunne; Roger Grogan; Stephen MacNally; David Fitzpatrick; Clare Faul Journal: Cancer Med Date: 2019-07-04 Impact factor: 4.452
Authors: Philip C De Witt Hamer; Philip C De Witt Hamer; Martin Klein; Shawn L Hervey-Jumper; Jeffrey S Wefel; Mitchel S Berger Journal: Neurosurgery Date: 2021-03-15 Impact factor: 4.654
Authors: Ivar Kommers; Linda Ackermans; Hilko Ardon; Wimar A van den Brink; Wim Bouwknegt; Rutger K Balvers; Niels van der Gaag; Lisette Bosscher; Alfred Kloet; Jan Koopmans; Mark Ter Laan; Rishi Nandoe Tewarie; Pierre A Robe; Olivier van der Veer; Michiel Wagemakers; Aeilko H Zwinderman; Philip C De Witt Hamer Journal: J Neurooncol Date: 2021-01-28 Impact factor: 4.130